Coherence Neuro has successfully raised $10 million in a seed funding round to advance its groundbreaking brain-computer interface (BCI) technology, SOMA-1, which aims to revolutionize cancer treatment. Co-founders Elise Jenkins and Ben Woodington announced the funding, which supports the development of their therapeutic device designed to monitor and stimulate the brain to combat cancer. The SOMA-1 device consists of a wireless, coin-sized implant that works with an over-ear wearable, providing continuous power and memory. It offers real-time insights and tracks symptoms through the SOMA app.
The innovative system targets cancer’s bioelectric signals directly, allowing for personalized treatment without affecting the entire body. It is MRI-transparent and facilitates home-based care, reducing hospital visits. Using AI, the device decodes electrical signals to identify tumor characteristics and adapt therapies accordingly. Jenkins emphasized the goal of merging neurotechnology and AI to create a bi-directional system that adjusts to disease progression. The recent funding will propel the company toward its first human trials.
The seed round was led by Artesian & Topology Ventures, with participation from previous investors and new supporters. The BCI market is witnessing growing interest, with companies like Neuralink and Synchron already making strides in implant technology. Other players in the field, such as Precision Neuroscience and Ability Neurotech, are also advancing their BCI platforms, highlighting the sector’s rapid development and potential to transform medical treatments.
